ColinDevinant

Associate

巴黎 + 33.1.56.59.38.71

联系：

Share

Colin Devinant's practice centers on national and international patent litigation. He has experience working on contentious and noncontentious matters in France and abroad (Germany, U.S., UK) for start-up and international groups involving patent rights across many technical fields (mechanics, chemistry, electronics, cosmetics, packaging, transports, consumer products, medical devices, agrochemical products, construction, biosimilars, generics).

Colin's primary focus is on patent validity and infringement litigation as well as on compensation for employee inventions and patent ownership claims. He also drafts and negotiates confidentiality, license, research, and technology transfer agreements and performs IP due diligence in support of M&A deals.

Prior to joining Jones Day in 2018, Colin practiced patent litigation in the Paris office of a U.S.-based international law firm and interned at a leading French patent litigation firm in Paris. His previous experience also includes serving as an intern in the IP legal department of a French research university, where he drafted and negotiated research and development (R&D) agreements, as well as for a French patent and trademark prosecution firm.

Colin has authored several publications discussing patent litigation, notably regarding software patents, generics, and the Unified Patent Court.

Colin is an active member of several of the main professional associations in IP: the International Association for the Protection of Intellectual Property (AIPPI) (member of the Executive Committee and of the Patents, UPC, and Young Members commissions), the Young EPLAW (European Lawyers), and the French Association for the Protection of Intellectual Property (AFPPI).

In 2024, he was ranked by The Legal 500 as a Rising Star in patent litigation.

经验

  • CJ CheilJedang enforces French patent against MetexJones Day represents CJ CheilJedang Corporation, a major Korean-based multinational company, in patent infringement litigation involving genetically engineered microorganisms for the production of certain essential amino acids before the French court.
  • Ahlström Capital BV and Nidoco AB invest in the Decor business of Ahlstrom-MunksjöJones Day advised Ahlström Capital BV and Nidoco AB in the acquisition of the Decor business of Ahlstrom-Munksjö.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • INAO obtains landmark decision in "Saucisson d'Avergne" protected geographical indicationJones Day successfully represented the French Institute of Origin and Quality (INAO) against a large producer of sausages and related products massively commercialized in large national supermarkets in France under the "Louis Auvergne" trademark, while its products could not benefit from the "Saucisson d'Auvergne" protected geographical indication.
  • Omnes Capital, Merieux Equity Partners, and Elaia Partners participate in €20 million financing round of SeqOne GenomicsJones Day advised Omnes Capital, Merieux Equity Partners, and Elaia Partners in the €20 million financing round of SeqOne Genomics, a French-based provider of next genomic analysis solutions for personalized medicine.
  • Elephant participates in €30 million Series B financing round of DataDomeJones Day represented Elephant as lead investor in the €30 million Series B round of financing of DataDome, a French leading bot protection vendor.
  • French biotech company seeks to audit and to improve existing trade secret protection policyJones Day is advising a French biotechnology company with respect to auditing and improving its existing trade secret protection policy.
  • Aurora Resurgence sells Alltub Group to One Equity PartnersJones Day advised Aurora Resurgence in the sale of portfolio company Alltub Group to One Equity Partners.
  • New Alpha participates in €4 million financing round of Fred de la comptaJones Day advised New Alpha Asset Management in connection with the €4 million (US$4.6 million) round of financing of Fred de la compta, a company providing a platform and data analysis tools in the field of accounting.
    •

    November 2024 Commentary

    Germany's Legal Privilege: What In-House Counsel Need to Know

    August 2021 White Paper

    2021 Mid-Year Review: Key Global Trade Secret Developments

    April 2020 White Paper

    Quick Reference Guide: Compulsory Patent Licensing During COVID-19 Crisis

    January 2020 Commentary

    French PACTE Act: Provisional Patent Application and the Evolution of the Utility Certificate

    • April 18, 2024
      AIPPI Trilateral Meeting Panel: Indirect Infringement in Cross-Border Situations

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice